IP Library Granted Patent US 12677825
Granted Patent B2
US 12677825 · App. 17/916,359 · Granted Jul 14, 2026

Composition for protecting islet transplantation

Inventors: Sang-Man Jin (Seoul, KR); Jae Hyeon Kim (Seoul, KR); Gyuri Kim (Seoul, KR); Han Sin Lee (Yongin-si, KR)
Assignee: LG CHEM, LTD.
A01N1/126C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12677825
App. No.
17/916,359
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention pertains to a composition having a protective effect during islet transplantation, and more specifically, to a composition containing a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, and capable of providing a protective effect against oxidative stress, inflammation, etc. during islet transplantation.

Claims (15)

1 . A method of protecting islets, comprising treating a pancreas during isolation of islets, or treating isolated islets during serum-deprived culture of isolated islets, with a compound of the following Formula 1 or a pharmaceutically acceptable salt thereof:

wherein

n is 0 or 1;

X is C and n is 1;

R 1 is hydrogen or C 1 -C 6 alkyl;

R 2 is phenyl;

R 3 is hydrogen or C 1 -C 6 alkyl;

R 4 is CH 2 -(1,1-dioxo-thiomorpholin-4-yl) or CH 2 -(2-oxopiperazin-4-yl);

R 5 is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; and

R 6 is tetrahydropyran or tetrahydrofuran,

wherein the compound of Formula 1 protects islets by reducing amounts of oxidative stress and reactive oxygen species (ROS).

2 . The method according to claim 1 , wherein the compound of Formula 1 is (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine of the following Formula 2:

3 . The method according to claim 1 wherein the compound of Formula 1 reduces the expression of c-jun N-terminal kinase, high mobility group box-1 (HMGB1), and and proinflammatory cytokines.

4 . The method according to claim 3 , wherein the proinflammatory cytokines are interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α).

5 . The method according to claim 1 , wherein the compound of Formula 1 reduces the accumulation of amyloid and toxic islet amyloid polypeptide (IAPP) oligomers.